{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T06:59:42Z","timestamp":1766386782976,"version":"3.48.0"},"reference-count":12,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2025,12,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This substudy investigated whether medicinal cannabis causes an elevation in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in patients with advanced malignancy and determined whether different cannabis formulations (cannabidiol (CBD) alone vs tetrahydrocannabinol (THC)\/CBD combination) had differing effects on enzyme levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This analysis used data from two multicentre, randomised, placebo-controlled trials of escalating doses of CBD (MedCan1) or THC\/CBD (MedCan2), including 287 patients with advanced cancer. Participants received escalating doses of CBD, THC\/CBD or placebo. ALT and AST levels were measured at baseline, day 14 and day 28.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Medicinal cannabis did not cause elevation of ALT or AST in patients with advanced malignancy at the doses studied (up to 600 mg CBD\/day). No clinically meaningful differences in liver enzyme levels were observed between CBD-only and CBD\/THC combination products. Furthermore, no patients in the cannabis groups exceeded the predefined thresholds of 3\u00d7 upper limit of normal (ULN) (or 5\u00d7 ULN in those with liver metastases) for ALT or AST.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with advanced malignancy enrolled in two clinical trials, medicinal cannabis products did not have a significant adverse impact on ALT or AST levels during the first 4\u2009weeks of use at the doses studied.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/spcare-2025-005837","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T06:55:23Z","timestamp":1766386523000},"page":"spcare-2025-005837","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Liver enzyme effects of medicinal cannabis in advanced cancer: a substudy of two randomised trials"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3253-7051","authenticated-orcid":false,"given":"Luke","family":"Scarborough","sequence":"first","affiliation":[{"name":"Supportive and Palliative Care, Mater Health Services Brisbane, South Brisbane, Queensland, Australia"},{"name":"St Gemma\u2019s Hospice, Leeds, West Yorkshire, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1127-9951","authenticated-orcid":false,"given":"Janet","family":"Hardy","sequence":"additional","affiliation":[{"name":"Department of Palliative, Supportive Care Mater Misericordiae Ltd, South Brisbane, Queensland, Australia"},{"name":"University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9695-9109","authenticated-orcid":false,"given":"Taylan","family":"Gurgenci","sequence":"additional","affiliation":[{"name":"School of Medicine, The University of Queensland, Saint Lucia, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2645-1685","authenticated-orcid":false,"given":"Georgie","family":"Huggett","sequence":"additional","affiliation":[{"name":"Mater Research Institute The University of Queensland, South Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Pelecanos","sequence":"additional","affiliation":[{"name":"Statistics Unit, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lachlan","family":"Webb","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1574-4729","authenticated-orcid":false,"given":"Ristan","family":"Greer","sequence":"additional","affiliation":[{"name":"Mater Research Institute The University of Queensland, South Brisbane, Queensland, Australia"},{"name":"Torus Research, Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8198-0375","authenticated-orcid":false,"given":"Phillip","family":"Good","sequence":"additional","affiliation":[{"name":"Supportive and Palliative Care, Mater Health Services, Brisbane, Queensland, Australia"},{"name":"Department of Palliative Care, St Vincent\u2019s Private Hospital, Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,21]]},"reference":[{"key":"2025122122551880000_spcare-2025-005837v1.1","doi-asserted-by":"crossref","first-page":"102698","DOI":"10.1016\/j.drugpo.2020.102698","article-title":"Evaluating the impacts of cannabis legalization: The International Cannabis Policy Study","volume":"77","author":"Hammond","year":"2020","journal-title":"Int J Drug Policy"},{"key":"2025122122551880000_spcare-2025-005837v1.2","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/j.jpainsymman.2022.06.002","article-title":"Cannabis in Palliative Care: A Systematic Review of Current Evidence","volume":"64","author":"Doppen","year":"2022","journal-title":"J Pain Symptom Manage"},{"key":"2025122122551880000_spcare-2025-005837v1.3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071412","article-title":"Review of the Use of Medicinal Cannabis Products in Palliative Care","volume":"16","author":"Troyer","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025122122551880000_spcare-2025-005837v1.4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1684\/epd.2019.1123","article-title":"Pharmacology and drug interactions of cannabinoids","volume":"22","author":"Landmark","year":"2020","journal-title":"Epileptic Disord"},{"key":"2025122122551880000_spcare-2025-005837v1.5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-induced liver injury","volume":"5","author":"Andrade","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2025122122551880000_spcare-2025-005837v1.6","unstructured":"FDA . What you need to know (and what we\u2019re working to find out) about products containing cannabis or cannabis-derived compounds, including CBD. US Food & Drug Administration; 2020."},{"key":"2025122122551880000_spcare-2025-005837v1.7","doi-asserted-by":"crossref","first-page":"2397847320922944","DOI":"10.1177\/2397847320922944","article-title":"Is cannabidiol hepatotoxic or hepatoprotective: A review","volume":"4","author":"Stohs","year":"2020","journal-title":"Toxicology Research and Application"},{"key":"2025122122551880000_spcare-2025-005837v1.8","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/joim.13627","article-title":"Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis","volume":"293","author":"Lo","year":"2023","journal-title":"J Intern Med"},{"key":"2025122122551880000_spcare-2025-005837v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70279-1"},{"key":"2025122122551880000_spcare-2025-005837v1.10","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.22.01632","article-title":"Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD)","volume":"41","author":"Hardy","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025122122551880000_spcare-2025-005837v1.11","doi-asserted-by":"crossref","first-page":"12020","DOI":"10.1200\/JCO.2024.42.16_suppl.12020","article-title":"A randomized, double-blind controlled trial of medicinal cannabis vs placebo for symptom management in patients with advanced cancer receiving palliative care","volume":"42","author":"Hardy","year":"2024","journal-title":"JCO"},{"key":"2025122122551880000_spcare-2025-005837v1.12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27854"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2025-005837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T06:55:27Z","timestamp":1766386527000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2025-005837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,21]]},"references-count":12,"alternative-id":["10.1136\/spcare-2025-005837"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2025-005837","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,21]]}}}